Enveric Biosciences
ENVB
3 hedge funds and large institutions have $144K invested in Enveric Biosciences in 2020 Q4 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.
620% more capital invested
Capital invested by funds: $20K → $144K (+$124K)
0.16% more ownership
Funds ownership: 0.02% → 0.17% (+0.16%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$52.5K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$52.5K |
| 3 |
VF
Virtu Financial
New York
|
+$52.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
-$14K |
ENVB Hedge Fund Activity: Q4 2020 in Review
3 of the 5,677 institutional investors tracked by Wall St. Rank reported a position in Enveric Biosciences (ENVB) for Q4 2020, worth a combined $144K — up 620% from $20K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ENVB positions and 0 closed out — a net gain of 3 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $52.5K. The largest seller was Geode Capital Management, cutting an estimated $14K.
- 3 institutional investors held Enveric Biosciences (ENVB) as of Q4 2020, up from 0 in Q3 2020.
- Funds reported $144K of Enveric Biosciences stock for Q4 2020, up 620% quarter-over-quarter.
- 3 funds opened new Enveric Biosciences positions in Q4 2020 and 0 closed out, a net change of +3 holders.
- The largest Enveric Biosciences buyer in Q4 2020 was Citadel Advisors, an estimated $52.5K added.
- The largest Enveric Biosciences seller in Q4 2020 was Geode Capital Management, an estimated $14K sold.
Based on aggregated 13F filings for Q4 2020.